[1] 徐淑芬, 白海, 王存邦, 等. 硼替佐米为主方案与常规化疗方案治疗多发性骨髓瘤疗效比较[J]. 现代肿瘤医学,2015,23(11):1585-1588.
[2] Richardson PG, Delforge M, Beksac M, et al.Management of treatment-emergent peripheral neuropathy in multiple myeloma[J]. Leukemia,2012,26(4):595-608.
[3] 王凡, 赵春亭. 硼替佐米致周围神经病变机制的研究进展[J]. 中华临床医师杂志(电子版),2013,7(6):2641-2643.
[4] Chen D, Frezza M, Schmitt S, et al.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives[J]. Curr Cancer Drug Targets,2011,11(3):239-253.
[5] Casafont I, Berciano M T, Lafarga M.Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons[J]. Neurotox Res,2010,17(2):167-178.
[6] Poruchynsky MS, Sackett DL, Robey RW, et al.Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition[J]. Cell Cycle,2008,7(7):940-949.
[7] Azoulay D, Lavie D, Horowitz N, et al.Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma[J]. Br J Haematol,2013,164(3):454-456.
[8] 马瑜瑾, 李世朋. 沙利度胺对肝癌细胞 HepG2化疗的增敏作用[J]. 中国临床药理学杂志,2014(7):597-600.
[9] 刘文彬. 沙利度胺联合化疗治疗多发性骨髓瘤患者的疗效观察[J]. 中国当代医药,2012,19(19):91-92.
[10] Johnson DC, Corthals SL, Walker BA, et al.Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma[J]. J Clin Oncol,2011,29(7):797-804.
[11] 中国医师协会血液科医师分会多发性骨髓瘤专业委员会. 多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J]. 中华内科杂志, 2015,54(9):821-824.
[12] Morawska M, Grzasko N1, Kostyra M, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations[J]. Hematol Oncol,2015,33(4):113-119.
[13] Morawska M, Grzasko N, Kostyra M, et al.Therapy-rela-ted peripheral neuropathy in multiple myeloma patients[J]. Hematol Oncol,2014,33(4):113-119.
[14] Palumbo A, Mateos MV, Bringhen S, et al.Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?[J]. Blood Rev,2011,25(4):181-191.
[15] 邵力, 王莎莎, 孟海涛, 等. 多发性骨髓瘤患者硼替佐米治疗后周围神经病变的发生情况[J]. 中华医学杂志,2015,95(40):3297-3301.
[16] Jakubowiak AJ.Evolution of carfilzomib dose and sche-dule in patients with multiple myeloma: a historical overview[J]. Cancer Treat Rev,2014,40(6):781-790.
[17] Glasmacher A, Hahn C, Hoffmann F, et al.A systematic review of phase-Ⅱ trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma[J].Br J Haematol,2006,132(5):584-593.
[18] 杨丕坚, 李舒敏, 吕以培, 等. 鼠神经生长因子治疗糖尿病痛性神经病变疗效观察[J]. 中华实用诊断与治疗杂志,2013,27(6):589-591.
[19] Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diag-nosis and management of multiple myeloma 2011[J]. Br J Haematol,2011,154(1):32-75.
[20] 范玉芳, 郑翠苹, 吴圣豪, 等. 多发性骨髓瘤周围神经病变研究进展[J]. 中华临床医学杂志,2015,30(6):710-714.
[21] 王焰, 张赟翔, 范青叶, 等. 23例免疫球蛋白D型多发性骨髓瘤的临床诊治经验[J]. 内科理论与实践,2016, 11(3):165-169.
